Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Slowing lung damage in idiopathic pulmonary fibrosis: Losartan plus Pirfenidone
IRCT20250508065656N1Phase 3Recruiting
- Sponsor
- Shahid Sadoughi University of Medical Sciences
- Start
- May 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3 trial of pirfenidone and losartan in idiopathic pulmonary fibrosis (IPF), sponsored by Shahid Sadoughi University of Medical Sciences. Started May 2025; status: recruiting.
02
Drugs
pirfenidonelosartan
03
Conditions
idiopathic pulmonary fibrosis (IPF)
Beyond the preview
Go deeper on IRCT20250508065656N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20250508065656N1.